Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine (SKYCellflu^® QIV) in Children and Adolescents: A Multicenter Test-Negative Case-Control Study in Korea.

ABSTRACT: Background: Children and adolescents are pivotal in the transmission of influenza, and vaccination remains the most effective preventive measure. Cell-based influenza vaccines offer advantages over traditional egg-based vaccines by reducing egg-adapted mutations and improving antigenic match. SKYCellflu^® quadrivalent influenza vaccine (QIV; SK bioscience, Korea), the first cell-based QIV licensed in Korea for individuals aged 6 months and older, offers potential advantages; however, its real-world effectiveness in the Korean pediatric population remains limited. Objective: This study aimed to estimate the real-world effectiveness of SKYCellflu^® QIV, a cell-based QIV, in preventing laboratory-confirmed influenza among children and adolescents aged 6 month

SUBMITTER: Yoon Y 

PROVIDER: S-EPMC12846570 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature